Today: 7 February 2026
Subscribe
Browse Category

LSE:GSK News 20 September 2025 - 10 December 2025

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance.Stock Titan+1 Below is a deep dive into today’s news, how GSK shares are trading, what analysts are forecasting, and where the risk/reward balance looks to be heading into 2026. This is information, not personalised investment advice. GSK share price today: still near the top of its 2025
10 December 2025
······
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and largely defused one of the biggest litigation overhangs in the sector. On the NYSE, GSK ADRs change hands around $48–49, very near their 52‑week high of $49.31, and up roughly 37% over the past year, versus about 14% for the S&P 500 over the same period. Yahoo Finance+1 On the London Stock Exchange, GSK trades around £18.0, also just below
9 December 2025
······
GSK Stock Today, December 8, 2025: Price, Buyback, CEO Change and 2026 Forecast

GSK Stock Today, December 8, 2025: Price, Buyback, CEO Change and 2026 Forecast

Updated 8 December 2025 GSK share price snapshot GSK plc (LON: GSK; NYSE: GSK) heads into the second week of December trading near its 52‑week highs after a year of strong execution in specialty medicines and a powerful buyback programme. In simple terms: GSK stock has already re-rated sharply in 2025 and now trades as a large‑cap growth/value hybrid rather than the deeply discounted “problem child” it looked like a couple of years ago. Latest corporate news: Q3 beat, guidance upgrade and accelerating buyback Strong Q3 2025 performance On 29 October 2025, GSK reported a better‑than‑expected third quarter and raised
8 December 2025
····
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK share price today, latest news, dividend, buyback activity and stock forecast as of 5 December 2025. GSK Share Price: Trading Near Multi‑Year Highs After a Strong 2025 GSK plc (LON:GSK; NYSE:GSK) is heading into year‑end 2025 on the front foot. As of the latest close before 5 December 2025, GSK’s London‑listed shares were trading around 1,826–1,837p, while the NYSE‑listed ADR ended at about $48.57 on 4 December.Investing.com+2Shares Magazine+2 That puts the stock close to its 52‑week highs of roughly $48.7 for the ADR and just below recent peaks in London, after a powerful run from roughly $34 per ADR
5 December 2025
······
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts are still only lukewarm on the stock, and long‑term growth expectations lag management’s ambitions. This is a deep dive into where GSK stock stands today, what’s driving the rally, and what current news and forecasts are signalling about 2026 and beyond. GSK share price today and 2025 performance On the NYSE, GSK’s U.S. ADR is trading around $48.27 in early
3 December 2025
······
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now. 1. Medicare’s New Drug Prices Hit GSK’s Trelegy and Breo Ellipta The biggest GSK headline today comes from Washington: Medicare has released the second round of negotiated prices for 15 of its costliest prescription medicines, with two GSK respiratory products on the list. Newsweek+3Reuters+3pharmaphorum+3 Key details: These new prices are scheduled to
26 November 2025
···
1 … 3 4 5

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop